

Dupuytren's Disease Market Set To Reach \$5.76 Billion By 2029 At A CAGR Of 6.0%

*The Business Research Company's
Dupuytren's Disease Market Set To Reach
\$5.76 Billion By 2029 At A CAGR Of 6.0%*

LONDON, GREATER LONDON, UNITED
KINGDOM, May 9, 2025

/EINPresswire.com/ -- [The Business Research Company's](#) Latest Report
Explores Market Driver, Trends,
Regional Insights - Market Sizing &
Forecasts Through 2034

The Business
Research Company

Dupuytren's Disease Global Market Report 2025 -
Market Size, Trends, And Global Forecast 2025-2034

How Big Is the Dupuytren's Disease Market and How Fast Is It Growing?

The global dupuytren's disease market is experiencing steady growth, valued at \$4.28 billion in 2024 and projected to reach \$4.55 billion in 2025, registering a compound annual growth rate (CAGR) of 6.3%. This upward trajectory is fueled by demographic trends such as an aging population, a genetic predisposition to the disease, and lifestyle-related factors like diabetes and alcohol consumption.

“

It will grow to \$5.76 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%.

”

*The Business Research
Company*

Looking ahead, the market is expected to continue its robust growth, reaching \$5.76 billion by 2029 at a CAGR of

6.0%. The future outlook is driven by greater awareness, increasing healthcare investments, and a shift toward minimally invasive treatments.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample_request?id=21944&type=smp

What Are the Key Trends Shaping the Dupuytren's Disease Market?

Innovations are reshaping the dupuytren's disease treatment landscape. Major trends include the advancement of gene therapies and stem cell solutions targeting fibrotic conditions, the development of AI-powered diagnostic tools, and the use of 3D printing for custom orthotics. Additionally, companies like Ventoux Biosciences are working on disease-modifying therapies,

such as VEN-201, to offer non-surgical alternatives that could transform standard care.

What Is Driving the Dupuytren's Disease Market's Growth?

A major growth driver for the Dupuytren's disease market is the increasing preference for minimally invasive treatments, which offer faster recovery, reduced complications, and improved patient satisfaction. For example, the use of robotic-assisted surgical platforms like da Vinci has seen a 12% rise in Australia, reflecting a broader global trend. These methods not only restore hand function effectively but also decrease hospitalization time and associated costs.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/dupuytren-s-disease-global-market-report>

Who Are the Leading Players in the Dupuytren's Disease Market?

The market features a mix of global pharmaceutical companies, orthopedic institutions, and medical technology innovators. Prominent players include:

Pfizer Inc., Aetna Inc., Mayo Clinic, Endo Inc., Mercy Health, Ventoux Biosciences Inc., 180 Life Sciences Corp., University of Utah Health, Connex Inc., OSS Health, and Sumitomo Dainippon Pharma Co. Ltd.

Notably, Endo Inc. partnered with John Elway Dealership Group in 2024 to promote awareness of Dupuytren's contracture and support the use of XIAFLEX, a non-surgical treatment option.

What Are the Segments in the Dupuytren's Disease Market?

The Dupuytren's disease market is segmented by:

- By Disease Type:
 - o Type I: Classical Dupuytren's Disease, Familial Dupuytren's Disease
 - o Type II: Palmar Fasciitis, Ledderhose Disease
 - o Type III: Garrod's Pads, Peyronie's Disease
- By Treatment:
 - o Surgery
 - o Radiation Therapy
 - o Needle Aponeurotomy
 - o Steroid Shot
 - o Enzyme Injection
 - o Occupational Therapy
 - o Other Treatments
- By Route of Administration:
 - o Oral
 - o Parenteral
 - o Other Routes
- By Diagnosis:
 - o Physical Examination

- o X-Ray
- o Other Diagnosis
 - By End-User:
- o Hospitals
- o Clinics
- o Academic and Research Institutes
- o Other End-Users

Which Regions Are Leading the Dupuytren's Disease Market Expansion?

North America holds the largest share of the Dupuytren's disease market, thanks to high healthcare spending, strong diagnostic infrastructure, and greater disease awareness.

Meanwhile, Asia-Pacific is emerging as the fastest-growing region due to rising healthcare access, an expanding aging population, and increasing research investments. Countries such as China, India, and Japan are key growth drivers in the region.

Request Customised Information On This Market Here:

<https://www.thebusinessresearchcompany.com/Customise?id=21944&type=smp>

Browse Through More Similar Reports By The Business Research Company:

Alzheimer's Disease Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report>

Oral Biologics & Biosimilar Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report>

Radiation Dose Management Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/radiation-dose-management-global-market-report>

About The Business Research Company

Learn More About The Business Research Company.

With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights.

Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas: +1 3156230293

Asia: +44 2071930708

Europe: +44 2071930708

Email us: info@tbrc.info

Stay connected:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/811052233>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.